<DOC>
	<DOC>NCT00994890</DOC>
	<brief_summary>This study will investigate the safety of three fixed dose levels of tanezumab (2.5 mg, 5 mg, and 10 mg) administered at an 8-week interval by subcutaneous injection multiple (7) times during the study treatment period.</brief_summary>
	<brief_title>A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections</brief_title>
	<detailed_description>Safety study of tanezumab in relief of osteoarthritis pain This study was terminated on 6 December 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Osteoarthritis, Hip</mesh_term>
	<criteria>Osteoarthritis of the knee or hip based on American College of Rheumatology criteria with a radiographic (X ray) confirmation (a Kellgren Lawrence xray grade of â‰¥2); Body mass index (BMI) of &gt;39 kg/m2; Pregnancy or intent to become pregnant Planned surgical procedure during the duration of the study History of clinically significant cardiovascular, central nervous system or psychiatric disease Previous exposure to exogenous NGF or to an anti NGF antibody; Use of biologics other than study medication, Live or liveattenuated intranasal vaccines (eg, Flumist), are allowable exceptions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Double-blind safety</keyword>
</DOC>